about
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma.Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field.Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myelomaLonger procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Thrombosis in multiple myeloma (MM).
@en
type
label
Thrombosis in multiple myeloma (MM).
@en
prefLabel
Thrombosis in multiple myeloma (MM).
@en
P2860
P1433
P1476
Thrombosis in multiple myeloma (MM)
@en
P2093
Esteban Braggio
P2860
P304
P356
10.1179/102453312X13336169156933
P478
17 Suppl 1
P577
2012-04-01T00:00:00Z